Skip to main content
NewslettersWatchlist

Ardelyx Inc(ARDX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low5.91
Day High6.25
Open:5.99
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
3 Small-Cap Stocks Set To Skyrocket
The Globe and Mail
14 top U.S. equities to watch for price trend chasers
Motley Fool
Why Ardelyx Stock Soared Today
Motley Fool
Why Ardelyx Stock Popped Today
AllPennyStocks.com
Biotech Finds Mid-Week Success Following FDA Announcement
Motley Fool
Why Shares of Ardelyx Were Down Wednesday
Barchart
Markets Today: Stock Indexes Push Higher Ahead of Fed Chair Powell’s Speech
Barchart
S&P Futures Tick Higher Ahead of Powell’s Jackson Hole Speech
PR Newswire
Ardelyx, Inc. Reports Employment Inducement Grants
Barchart
Chart of the Day: Ardexlyx - Biotechnology
PR Newswire
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
PR Newswire
Ardelyx, Inc. Reports Employment Inducement Grants
Barchart
Pre-Market Brief: Stocks Mixed As Recession, Rate Hike Fears Persist
PR Newswire
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
PR Newswire
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
MarketBeat
Is Ardelyx is A Buy After Slip in Early 2022
Motley Fool
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
PR Newswire
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
PR Newswire
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
PR Newswire
Ardelyx, Inc. Reports Employment Inducement Grants
PR Newswire
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
PR Newswire
Ardelyx, Inc. Reports Employment Inducement Grants

Profile

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.